At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 80 enrolled
Drug / intervention
Abatacept +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
In Brief
A Phase 4 clinical trial evaluating Abatacept, Adalimumab, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 80 participants across 28 sites in 3 countries.
Detailed Summary
The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with methotrexate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesCanada, Mexico, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartNov 2015
Primary CompletionMar 2019
TodayJul 2026
First PostedSep 23, 2015
Enrollment StartNov 19, 2015
Primary CompletionMar 28, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.8 years ago
Interventions
Abataceptdrug
Adalimumabdrug
Methotrexatedrug